Sensorion SA

ALSEN

Company Profile

  • Business description

    Sensorion SA is a France-based clinical-stage biotech company dedicated to developing therapies to restore, treat, and prevent hearing loss. The company's product is in phase 2a clinical development, SENS-401 (Arazasetron) in Sudden Sensorineural Hearing Loss (SSNHL). SENS-401 is being developed to treat cochlear pathologies. The Company does business in a single operating segment: conducting research and development to discover drugs to treat inner ear disorders with a view to their future marketing. The company's pipeline programs are SENS-401 SSNHL, SENS-401 CIO, GJB2-GT, GJB2-GT, SENS-401 Cochlear, and others.

  • Contact

    375, rue du Professeur Joseph Blayac
    Montpellier34080
    FRA

    T: +33 467207730

    https://www.sensorion.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    68

Stocks News & Analysis

stocks

Undervalued ASX founder-led companies

Can this strategy pick the winners?
stocks

AI stocks post big gains in Q3. These are the winners and losers

Alphabet and Teradyne post big gains, while Salesforce and Adobe were down in the quarter.
stocks

12 picks for an income portfolio - Q3 2025 update

Fifteen months in and passive income growth has exceeded my target.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,253.6025.70-0.28%
CAC 407,984.5612.780.16%
DAX 4024,400.2321.940.09%
Dow JONES (US)46,694.9763.31-0.14%
FTSE 1009,477.291.85-0.02%
HKSE26,957.77183.15-0.67%
NASDAQ22,941.67161.160.71%
Nikkei 22547,950.886.120.01%
NZX 50 Index13,531.2942.050.31%
S&P 5006,740.2824.490.36%
S&P/ASX 2008,956.8019.10-0.21%
SSE Composite Index3,882.7820.250.52%

Market Movers